Effects of intranasal 17 β-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 7, 1999, Pages 2390-2397

  Garnero, Patrick ^a   Tsouderos, Yannis ^b   Marton, Istvan ^c   Pelissier, Clara ^d   Varin, Claire ^b   Delmas, Pierre D ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c MAV Hospital   (Hungary)

^d HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRADIOL VALERATE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; ALKALINE PHOSPHATASE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; OSTEOCALCIN; PEPTIDE; PLACEBO;

ADULT; ARTICLE; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; BONE REMODELING; COMPARATIVE STUDY; INTRANASAL DRUG ADMINISTRATION; KINETICS; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; URINE;

ADMINISTRATION, INTRANASAL; ALKALINE PHOSPHATASE; BONE REMODELING; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; KINETICS; MIDDLE AGED; OSTEOCALCIN; PEPTIDES; PLACEBOS; POSTMENOPAUSE;

EID: 0033237664     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.84.7.5848     Document Type: Article

References (52)

1. Long-term prevention of postmenopausal osteoporosis by estrogen. Evidence for an increased bone mass after delayed onset of estrogen treatment
2. Long-term estrogen replacement therapy prevents bone loss and fractures
3. Hormone replacement therapy and the risk for first hip fracture. A prospective, population based cohort study
4. Effects of transdermal vs. oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women
5. Hormone replacement therapy in the prevention and treatment of osteoporosis
6. Plasma BGP: An indicator of spontaneous bone loss and effect of estrogen treatment in postmenopausal women
7. Impact of short-term estrogen administration on growth hormone secretion and action: Distinct route-dependent effects on connective and bone tissue metabolism
8. Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: Effect of physiological estrogen replacement
9. Growth hormone and somatomedin C during postmenopausal replacement therapy with oestrogen alone and in combination with antioestrogen
10. Effects of estrogen and sex difference on secretion of growth hormone
11. Effects of progestin-opposed transdermal estrogen administration on growth hormone and insuline-like growth factor-I in postmenopausal women of different ages
12. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth factor hormone (GH) secretion, insulin-like growth factor 1, and G-binding protein in postmenopausal women
13. Biological effects of estradiol 17β in postmenopausal women
14. Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonathrophin release, bone turnover and climateric symptoms in postmenopausal women
15. Biological effects of transdermal estradiol
16. Long-term effects of transdermal and oral replacement therapy on postmenopausal bone loss
17. A placebo comparison of non oral estradiol delivery in postmenopausal women
18. A randomized study to compare the effectiveness, tolerability of two different transdermal estradiol replacement therapies. The transdermal HRT investigators group
19. Acceptability and skin reactions to transdermal estrogen therapy in relation to climate
20. The nasal delivery of systemic drugs
21. Intranasal estradiol administration to oophorectomized women
22. Pharmacology and pharmacokinetics of estrogens
23. Efficacy and acceptability of intranasal 17β-oestradiol on menopausal symptoms: A randomized dose-response study
24. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay
25. Immunoassay for intact amino-terminal propeptide of human type I procollagen
26. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease
27. Immunoassay for quantifying type I collagen degradation products in urine evaluated
28. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease
29. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
30. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density
31. Short-term effects of transdermal 17β-oestradiol (ESTRADERM TTS) on bone metabolism in oophorectomized women: A placebo-controlled study
32. Effect of transdermal 17β-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause
33. 17β Oestradiol acts directly on the clonal osteoblastic cell line UMR-106
34. Enhanced osteoblast proliferation, and collagen gene expression by estradiol
35. Effect of 17β estradiol on human osteosarcoma cell line MG-63
36. Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation
37. High-dose estrogen inhibits bone resorption and stimulates bone formation in the ovariectomized mouse
38. Does estrogen stimulate osteoblast function in postmenopausal women?
39. Insulin-like growth factors and their binding proteins: Biological actions
40. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF-I binding proteins 1 and 3: A cross-over study
41. Serum IGF-1 and binding proteins 1 and 3 in postmenopausal women and the effects of estrogen
42. Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy
43. Differential effects of estrogen and growth hormone on uterine and hepatic insulin-like growth factor 1 in the ovariectomized hypophysectomized rat
44. Isolation of a novel IGF binding protein from human bone: A potential candidate for fixing IGF-II in human bone
45. Insulin-like growth factors I and II are present in the skeletal tissues of ten vertebrates
46. Serum levels of insuline-like growth factor (IGF) I and IGF-Biding protein (IGFBP)-2 and IGFBP-3 in osteoporotic patients with and without spinal fractures
47. Growth hormone-dependent insuline-like growth factor binding protein is a major determinant of bone mineral density in healthy men
48. IGF-I has independent effects on bone matrix formation and cell replication
49. Regulatory effects of IGF-I and IGF II on bone collagen synthesis in rat calvarial cultures
50. Effects of bone associated growth factors on DNA, collagen and osteocalcin synthesis in cultured rat calvariae
51. Insuline like growth factor I, hormonal regulation by growth hormone and 1,25 D3 and activity on human osteoblast-like cells in short-term cultures
52. Estradiol effects on proliferation, mRNA for collagen and IGF-I and PTH stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones